⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10758546 | 1.00 | — | — | |
| SCHEMBL336731 | 1.00 | — | — | |
| SCHEMBL63706 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL3635377 | 0.98 | HTR6 (0.83) | — | |
| Hydrochloric Acid SCHEMBL3639440 | 0.98 | HTR6 (0.83) | — | |
| Bromide SCHEMBL23116331 | 0.98 | HTR6 (0.83) | — | |
| Hydrochloric Acid SCHEMBL3633006 | 0.98 | HTR6 (0.83) | — | |
| Bromide SCHEMBL23116334 | 0.98 | HTR6 (0.83) | — | |
| Hydrochloric Acid SCHEMBL3635374 | 0.98 | HTR6 (0.83) | — | |
| SCHEMBL1190916 | 0.93 | HTR6 (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384789-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | claimed |
| CN-119528903-A | Compounds for the treatment of spinal muscular atrophy | PTC医疗公司 | 2025-02-28 | — | — | CN | claimed |
| CN-111065626-B | Compounds for the treatment of huntington's disease | PTC医疗公司 | 2024-09-27 | — | — | CN | claimed |
| WO-2024138018-A1 | TREATMENT OF GEMIN5-MEDIATED DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-06-27 | — | — | WO | claimed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | claimed |
| EP-4151627-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2022-08-11 | — | — | US | claimed |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-26 | — | — | US | claimed |
| CN-104244944-B | For treating the compound of spinal muscular atrophy | PTC医疗公司 | 2018-06-08 | — | — | CN | claimed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | claimed |
| EP-2842946-B1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-09-28 | — | — | EP | claimed |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-22 | — | — | US | claimed |
| EP-3061749-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-08-31 | — | — | EP | claimed |
| CN-105829285-A | Quinazolinone and isoquinolinone derivatives | 中外制药株式会社 | 2016-08-03 | — | — | CN | claimed |
| US-20150141400-A1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-05-21 | — | — | US | claimed |
| EP-2842946-A1 | QUINAZOLINEDIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | claimed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731623-A1 | CARBOLINE COMPOUNDS AND USE THEREOF | PTC Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-5576314-A | Bicyclic nonane and decane compounds having dopamine receptor affinity | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1996-11-19 | — | — | US | disclosed |
| WO-1996018630-A1 | BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1996-06-20 | — | — | WO | disclosed |